Institut Pasteur de Madagascar begins MpOx trial enrollment with backing from Emergent Biosolutions

Institut Pasteur de Madagascar begins MpOx trial enrollment with backing from Emergent Biosolutions
MpOx study begins in Madagascar

Emergent Biosolutions, together with PANTHER Health and Africa CDC, has initiated the MpOx Study in Africa (MOSA), with the first patient enrolled in Madagascar. The launch follows a recent declaration of an mpox outbreak in the country.

Institut Pasteur de Madagascar will lead the study to better understand the disease and inform potential response strategies. The partnership aims to accelerate research into mpox transmission and treatment options as the outbreak evolves. Details regarding the study's timeline and scope are still being clarified.

Emergent Biosolutions has previously focused on public health interventions, such as evaluating the safety and pharmacokinetics of multi-dose intranasal naloxone for opioid overdose response. The current mpox study expands the company's involvement in infectious disease research. Updates on the study's progress are expected as more patients are enrolled.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.